The COVID-19 pandemic has fast-tracked adoption of many healthcare technologies, but there is still room for growth. Prior to COVID-19, only 11 percent of patients used telehealth services. According to data released in June, 67 percent said they are more likely to use telehealth services moving forward.
A quarter of healthcare organizations’ revenue is tied to value-based payments, according to a survey by the healthcare data analytics and policy company DataGen. Those with 550 or more beds reported the largest portion of risk, with an average of 37.9 percent of revenue tied to VBP.
The Bloc’s Dan Sontupe explores why the failure to educate patients about their conditions and treatment plans is a far bigger driver of healthcare costs than the price of prescription drugs.
A surge of U.S. policymakers and payers are endeavoring to shift providers’ financial incentives from those that pay for fee-for-service and greater volume of care to those that pay for high-value care. While there are some who resist this change, the die is cast as value-based contracting is delivering benefits to those who pay the bills.
Blue Cross Blue Shield of Massachusetts’ Alternative Quality Contract slowed the rate of medical spending growth by up to 12 percent while improving patient care over the course of eight years, according to a Harvard Medical School study published in the New England Journal of Medicine.
The American College of Surgeons and Harvard Business School’s Institute for Strategy and Competitiveness announced a new partnership aimed at improving health care value.
Healthcare consumers may love the idea of virtual care, but so far few are actually taking advantage of it. That’s the core message coming out of a recent Vivify Health survey, which showed 83 percent of consumers are interested in receiving virtual care, but only 17 percent have access to it.
Most U.S. consumers are very interested in receiving regular messages from their health plans – if those messages are highly relevant to them and can help them stay healthier and/or save money. That’s the conclusion drawn from a new online Pollfish survey of 400 consumers conducted on behalf of RxEOB who are members of commercial and government-sponsored health plans.
Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.
Continuing its efforts to address high prescription drug costs, insurer Highmark entered into a new outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.
